J. Safra Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

J. Safra Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-715	Closed	-$87K	–	79
2016 Q3	$87K	Hold	715	–	–	0.15%	36
2016 Q2	$101K	Buy	+715	New	+$105K	0.16%	57

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

J. Safra Asset Management's JAZZ Position: Q4 2016 in Review

J. Safra Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2016, closing a stake of 715 shares — an estimated $87K sold.

J. Safra Asset Management first reported a position in JAZZ in Q2 2016 and held it in 2 quarters. The position peaked at $101K in Q2 2016. 295 funds tracked by Wall St. Rank hold JAZZ as of Q4 2016.

J. Safra Asset Management reported no remaining Jazz Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
J. Safra Asset Management sold 715 Jazz Pharmaceuticals shares in Q4 2016, an estimated $87K.
J. Safra Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2016 and held it in 2 quarters.
J. Safra Asset Management's Jazz Pharmaceuticals position peaked at $101K in Q2 2016.
295 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2016.

Based on J. Safra Asset Management's 13F filing for Q4 2016, filed 9 Feb 2017.